Endostatin Gene Therapy for Liver Cancer by a Recombinant Adenovirus Delivery

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2004 Jun 29

PMID 15222025

Citations 10

Authors

Li Li

Jia-Ling Huang

Qi-Cai Liu

Pei-Hong Wu

Ran-Yi Liu

Yi-Xin Zeng

Wen-Lin Huang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the expression of adenovirus-mediated human endostatin (Ad/hEndo) gene transfer and its effect on the growth of hepatocellular carcinoma (HCC) BEL-7402 xenografted tumors.

Methods: Immunohistochemistry analysis with an anti-endostatin antibody was preformed to detect endostatin protein expression in HCC BEL-7402 cells infected with Ad/hEndo. MTT assay was used to investigate the effects of Ad/hEndo on proliferation of human umbilical vein endothelial cells (HUVEC). Intra-tumoral injections of 1X10(9) pfu Ad/hEndo was given to treat BEL-7402 xenografted tumors in nude mice once weekly for 6 wk. Mice received injections of Ad/LacZ and DMEM were regarded as control groups. After intra-tumoral administration with Ad/hEndo, the endostatin mRNA expression in tumor tissue was analyzed by Northern blotting, and plasma endostatin levels were determined using enzyme-linked immunosorbent assay (ELISA).

Results: High level expression of endostatin gene was detected in the infected HCC BEL-7402 cells. Ad/hEndo significantly inhibited HUVEC cell proliferation by 57.2% at a multiplicity of infection (MOI) of 20. After 6-week treatment with Ad/hEndo, the growth of treated tumors was inhibited by 46.50% compared to the Ad/LacZ control group (t=2.729, P<0.05) and by 48.56% compared to the DMEM control group (t=2.485, P<0.05). The ratio of mean tumor volume in treated animals to mean tumor volume in the control animals (T:C ratio) was less than 50% after 24 d of treatment. Endostatin mRNA in tumor tissue was clearly demonstrated as a band of approximately 1.2 kb, which was the expected size of intact and functional endostatin. Plasma endostatin levels peaked at 87.52+/-8.34 ng/mL at d 3 after Ad/hEndo injection, which was significantly higher than the basal level (12.23+/-2.54 ng/mL). By d 7, plasma levels dropped to nearly half the peak level (40.34+/-4.80 ng/mL).

Conclusion: Adenovirus-mediated human endostatin gene can successfully express endogenous endostatin in vitro and in vivo, and significantly inhibit the growth of BEL-7402 xenografted liver tumors in nude mice.

Citing Articles

Head and neck cancer: pathogenesis and targeted therapy.

Liu Y, Zhang N, Wen Y, Wen J MedComm (2020). 2024; 5(9):e702.

PMID: 39170944 PMC: 11338281. DOI: 10.1002/mco2.702.

Angiogenesis and lymphangiogenesis in corneal transplantation-A review.

Zhong W, Montana M, Santosa S, Isjwara I, Huang Y, Han K Surv Ophthalmol. 2017; 63(4):453-479.

PMID: 29287709 PMC: 6003844. DOI: 10.1016/j.survophthal.2017.12.008.

Efficacy of pEgr-1-endostatin combined with ionizing radiation on hypoxic conditions in nude mice bearing SKOV3 ovarian carcinoma.

Zhang Y, Li X, Yu Z, Shi X, Li Y, Wang W Oncol Lett. 2017; 13(3):1101-1108.

PMID: 28454220 PMC: 5403319. DOI: 10.3892/ol.2017.5559.

Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Poluzzi C, Iozzo R, Schaefer L Adv Drug Deliv Rev. 2015; 97:156-73.

PMID: 26518982 PMC: 4753091. DOI: 10.1016/j.addr.2015.10.012.

E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases.

Zhao P, Luo R, Wu J, Xie F, Li H, Xiao X J Cell Mol Med. 2015; 14(1-2):381-91.

PMID: 26065034 PMC: 3837610. DOI: 10.1111/j.1582-4934.2008.00548.x.

References

Herbst R, Hess K, Tran H, Tseng J, Mullani N, Charnsangavej C . Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002; 20(18):3792-803. DOI: 10.1200/JCO.2002.11.061. View

Chen P, Kovesdi I, Bruder J . Effective repeat administration with adenovirus vectors to the muscle. Gene Ther. 2000; 7(7):587-95. DOI: 10.1038/sj.gt.3301137. View

Reid T, Warren R, Kirn D . Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2003; 9(12):979-86. PMC: 7091735. DOI: 10.1038/sj.cgt.7700539. View

Ding I, Sun J, Fenton B, Liu W, Kimsely P, Okunieff P . Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 2001; 61(2):526-31. View

Mundhenke C, Thomas J, Wilding G, Lee F, Kelzc F, Chappell R . Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res. 2001; 7(11):3366-74. View

Kianmanesh A, Hackett N, Lee J, Kikuchi T, Korst R, Crystal R . Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther. 2001; 12(17):2035-49. DOI: 10.1089/10430340152677395. View

Geutskens S, van der Eb M, Plomp A, Jonges L, Cramer S, Ensink N . Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther. 2000; 7(16):1410-6. DOI: 10.1038/sj.gt.3301251. View

St George J . Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 2003; 10(14):1135-41. DOI: 10.1038/sj.gt.3302071. View

Boehm T, Folkman J, Browder T, OReilly M . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390(6658):404-7. DOI: 10.1038/37126. View

10.

Kim Y, Park Y, Park C . Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology. 2001; 38(2):160-6. DOI: 10.1046/j.1365-2559.2001.01064.x. View

11.

Liu Q, Muruve D . Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 2003; 10(11):935-40. DOI: 10.1038/sj.gt.3302036. View

12.

Folkman J . What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990; 82(1):4-6. DOI: 10.1093/jnci/82.1.4. View

13.

Molinier-Frenkel V, Le Boulaire C, Le Gal F, Gahery-Segard H, Tursz T, Guillet J . Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum Gene Ther. 2000; 11(13):1911-20. DOI: 10.1089/10430340050129521. View

14.

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

15.

Dhanabal M, Ramchandran R, Volk R, Stillman I, Lombardo M, Iruela-Arispe M . Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 1999; 59(1):189-97. View

16.

Folkman J . Antiangiogenic gene therapy. Proc Natl Acad Sci U S A. 1998; 95(16):9064-6. PMC: 33874. DOI: 10.1073/pnas.95.16.9064. View

17.

Reid T, Galanis E, Abbruzzese J, Sze D, Wein L, Andrews J . Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002; 62(21):6070-9. View

18.

Shi W, Teschendorf C, Muzyczka N, Siemann D . Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 2002; 9(6):513-21. DOI: 10.1038/sj.cgt.7700463. View

19.

Qian J, Feng G, Vogl T . Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol. 2003; 9(9):1885-91. PMC: 4656637. DOI: 10.3748/wjg.v9.i9.1885. View

20.

Folkman J . Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333(26):1757-63. DOI: 10.1056/NEJM199512283332608. View